Lower than expected uptake of new therapies impacts PBS spend

September 29, 2025 Latest News BioPharma

This is a preview of subscriber content

Subscribe now to continue reading.

According to the 2024-25 Final Budget Outcome, PBS spending was impacted by "lower-than-estimated uptake of highly specialised medicines by patients, and lower-than-estimated utilisation of on-site pharmacists by residential aged care facilities." …

Subscribe now to continue reading.

Latest Video

An exceptional outcome that must not become an exception
October 18, 2025 - Latest News
Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access
October 18, 2025 - Latest News
BMS says September outcome could set a new policy benchmark for access
October 18, 2025 - Latest News
New combination therapy sets landmark survival benchmark in bladder cancer treatment
October 19, 2025 - Latest News
Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer
October 18, 2025 - Latest News

Lower than expected uptake of new therapies impacts PBS spend

This is a preview of subscriber content

Latest Video

Most Read

An exceptional outcome that must not become an exception

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

BMS says September outcome could set a new policy benchmark for access

New combination therapy sets landmark survival benchmark in bladder cancer treatment

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

New Stories

'Patient-centric partnerships will unlock brighter and more equitable outcomes for all'

Vaccine confidence slips as Australians grow more concerned about access to healthcare

NZ's Pharmac proposes new rules to manage 'Options for Investment' list - make it shorter

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion

Sign In

Lower than expected uptake of new therapies impacts PBS spend

This is a preview of subscriber content

Latest Video

Most Read

An exceptional outcome that must not become an exception

Trump announces third MFN deal with a focus on fertility drug costs and expanding IVF access

BMS says September outcome could set a new policy benchmark for access

New combination therapy sets landmark survival benchmark in bladder cancer treatment

Landmark trial confirms survival benefit of Lilly therapy in high-risk early breast cancer

Follow Us

New Stories

'Patient-centric partnerships will unlock brighter and more equitable outcomes for all'

Vaccine confidence slips as Australians grow more concerned about access to healthcare

NZ's Pharmac proposes new rules to manage 'Options for Investment' list - make it shorter

Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies

Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum

Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome

Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion